Merck completes enrolment of Evobrutinib Phase III Trials ahead of ECTRIMS 2021

Darmstadt: Merck, a science and technology company, has recently announced enrolment has been completed in the Phase III EVOLUTION RMS clinical trial programme, which is evaluating the efficacy and...

Related Keywords

Norway ,Australia ,Iceland ,Liechtenstein ,Vienna ,Wien ,Austria ,Canada ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Gavin Giovannoni ,Patrick Vermersch ,Barbara Kornek ,Xavier Montalban ,University Of Lille ,Department Of Neurology ,Additional Company ,Hebron University Hospital ,European Commission ,Neuroimmunology Department Neurorehabilitation Unit ,London School Of Medicine ,Sclerosis Centre Of Catalonia Cemcat ,Global Head Of Development For The Healthcare ,European Union ,Research In Multiple Sclerosis ,University Of Vienna ,European Committee For Treatment ,European Committee ,Multiple Sclerosis ,Danny Bar Zohar ,Global Head ,Patients Receiving Cladribine Tablets ,Primary Results ,London School ,Vice President ,Director Neurology Neuroimmunology Department ,Neurorehabilitation Unit ,Multiple Sclerosis Centre ,Evobrutinib ,Merck ,Merck News ,Relapsing Multiple Sclerosis ,